Article

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs

2022-06-17

Abstract excerpt

Adeno-associated virus (AAV) vectors are promising modalities of gene therapy to address unmet medical needs. However, anti-AAV neutralizing antibodies (NAbs) hamper the vector-mediated therapeutic effect. Therefore, the NAb prevalence in the target population is vital in designing clinical trials with AAV vectors. Hence, updating the seroprevalence of anti-AAV NAbs, herein we analyzed sera from 100 healthy indivi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ef166677-0422-5a83-8b6d-b3690987001d
DOI: 10.1101/2022.06.16.22276528

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacsDOI 10.1101/2022.06.16.22276528Read

Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United StatesSemantic proximity Read

Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapiesSemantic proximity Read

Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disordersSemantic proximity Read

Strategy to detect pre-existing immunity to AAV gene therapySemantic proximity Read

Worldwide Epidemiology of Neutralizing Antibodies to Adeno‐Associated VirusesSemantic proximity Read

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read

Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.Semantic proximity Read

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsSemantic proximity Read

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapySemantic proximity Read

Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population CohortSemantic proximity Read

Adeno-Associated Virus Antibody Profiles in Newborns, Children, and AdolescentsSemantic proximity Read

Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive PatientsSemantic proximity Read